Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hough

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Neuropsychiatric Disease and Treatment|May 10, 2011
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophreniaSrihari Gopal, Joris Berwaerts, Isaac Nuamah, et al.
International Clinical Psychopharmacology|October 16, 2008
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studiesRobin Emsley, Joris Berwaerts, Mariëlle Eerdekens, et al.
Psychopharmacology Bulletin|October 15, 2016
Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with SchizophreniaDanielle Coppola, Rama Melkote, Caroline Lannie, et al.
CNS Drugs|June 30, 2017
Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter StudySrihari Gopal, Rosanne Lane, Isaac Nuamah, et al.
The Lancet. Psychiatry|February 24, 2020
Approval of esketamine for treatment-resistant depressionJaskaran B Singh, Ella J Daly, Maju Mathews, et al.
Journal of Autism and Developmental Disorders|December 6, 2012
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled studyJustine M Kent, Stuart Kushner, Xiaoping Ning, et al.
International Clinical Psychopharmacology|March 15, 2016
Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapyLarry Alphs, Henry A Nasrallah, Cynthia A Bossie, et al.
The Journal of Clinical Psychiatry|May 10, 2008
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studiesHerbert Y Meltzer, William V Bobo, Isaac F Nuamah, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 2, 2009
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaDavid Hough, Jean-Pierre Lindenmayer, Srihari Gopal, et al.
The International Journal of Neuropsychopharmacology|July 23, 2011
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaW Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Neuropsychiatric Disease and Treatment|May 10, 2011
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophreniaSrihari Gopal, Joris Berwaerts, Isaac Nuamah, et al.
International Clinical Psychopharmacology|October 16, 2008
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studiesRobin Emsley, Joris Berwaerts, Mariëlle Eerdekens, et al.
Psychopharmacology Bulletin|October 15, 2016
Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with SchizophreniaDanielle Coppola, Rama Melkote, Caroline Lannie, et al.
CNS Drugs|June 30, 2017
Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter StudySrihari Gopal, Rosanne Lane, Isaac Nuamah, et al.
The Lancet. Psychiatry|February 24, 2020
Approval of esketamine for treatment-resistant depressionJaskaran B Singh, Ella J Daly, Maju Mathews, et al.
Journal of Autism and Developmental Disorders|December 6, 2012
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled studyJustine M Kent, Stuart Kushner, Xiaoping Ning, et al.
International Clinical Psychopharmacology|March 15, 2016
Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapyLarry Alphs, Henry A Nasrallah, Cynthia A Bossie, et al.
The Journal of Clinical Psychiatry|May 10, 2008
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studiesHerbert Y Meltzer, William V Bobo, Isaac F Nuamah, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 2, 2009
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaDavid Hough, Jean-Pierre Lindenmayer, Srihari Gopal, et al.
The International Journal of Neuropsychopharmacology|July 23, 2011
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaW Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, et al.
Pageof 7